West Pharmaceutical Services (WST) stock plummeted 38% on Thursday, making it the biggest decliner in the S&P 500. The sharp ...

Following the earnings announcement, WST stock plummeted 38% due to its disappointing guidance. Over a broader timeframe, its ...

Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...

We recently compiled a list of the Weak Earnings, Outlook Drag Shares of These 10 Firms on Thursday. In this article, we are ...

West Pharmaceutical Services (WST) stock was upgraded to Buy at Deutsche Bank due to an attractive entry point post-selloff. Read more here.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...

KeyBanc analyst Paul Knight maintained a Buy rating on West Pharmaceutical Services (WST – Research Report) today and set a price target of ...

Shares of West Pharmaceutical Services Inc. rose 7.84% to $214.73 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.01% to ...

West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

West Pharmaceutical Services, Inc. reported an EPS of $1.82, beating the estimated $1.71 and showcasing its ability to exceed expectations. The company achieved a revenue of approximately $748.8 ...

Mankind Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services and Royalty Income for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, the company has ...